MA29662B1 - Compositions pour l'apport de medicaments hautement solubles dans l'eau - Google Patents

Compositions pour l'apport de medicaments hautement solubles dans l'eau

Info

Publication number
MA29662B1
MA29662B1 MA29665A MA29665A MA29662B1 MA 29662 B1 MA29662 B1 MA 29662B1 MA 29665 A MA29665 A MA 29665A MA 29665 A MA29665 A MA 29665A MA 29662 B1 MA29662 B1 MA 29662B1
Authority
MA
Morocco
Prior art keywords
compositions
delivery
highly water
soluble drugs
drugs
Prior art date
Application number
MA29665A
Other languages
English (en)
Inventor
Andrew Xian Chen
Original Assignee
Sd Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sd Pharmaceuticals Inc filed Critical Sd Pharmaceuticals Inc
Publication of MA29662B1 publication Critical patent/MA29662B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pour l'apport de médicaments hautement solubles dans l'eau (p. ex. alcaloïdes de la pervenche) et des procédés d'utilisation de ces compositions.
MA29665A 2004-07-12 2007-02-06 Compositions pour l'apport de medicaments hautement solubles dans l'eau MA29662B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/889,226 US7871632B2 (en) 2004-07-12 2004-07-12 Compositions for delivering highly water soluble drugs

Publications (1)

Publication Number Publication Date
MA29662B1 true MA29662B1 (fr) 2008-08-01

Family

ID=35541622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29665A MA29662B1 (fr) 2004-07-12 2007-02-06 Compositions pour l'apport de medicaments hautement solubles dans l'eau

Country Status (18)

Country Link
US (4) US7871632B2 (fr)
EP (1) EP1773294A4 (fr)
JP (1) JP4643641B2 (fr)
KR (1) KR20070032816A (fr)
CN (1) CN1859898B (fr)
AU (1) AU2005271873A1 (fr)
BR (1) BRPI0513178A (fr)
CA (1) CA2578574C (fr)
EA (1) EA012522B1 (fr)
EC (1) ECSP077238A (fr)
IL (1) IL180350A0 (fr)
MA (1) MA29662B1 (fr)
MX (1) MX2007000416A (fr)
NO (1) NO20070785L (fr)
RS (1) RS20070029A (fr)
TW (1) TW200607525A (fr)
WO (1) WO2006017246A2 (fr)
ZA (1) ZA200701167B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1925853B (zh) * 2004-07-28 2011-01-26 陈献 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
CN101472562A (zh) * 2006-05-12 2009-07-01 陈献 用于静脉刺激性药物的药物组合物
WO2009078754A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament permettant d'administrer des substances pharmaceutiquement actives faiblement hydrosolubles
WO2009078756A1 (fr) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement acceptable amphiphile, cationique et hydrosoluble
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
WO2009108689A1 (fr) * 2008-02-25 2009-09-03 Novavax, Inc. Particules pseudo-virales (vlp) associées à du sucre candi
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
EA201190135A1 (ru) * 2009-02-26 2012-07-30 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Композиции на основе эмульгированных наркотических веществ для лечения боли при раке
CN101879138A (zh) 2009-05-06 2010-11-10 上海恒瑞医药有限公司 长春花生物碱纳米乳剂注射液及其制备方法
CN102573475B (zh) * 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
NZ608406A (en) * 2010-10-22 2015-06-26 Reddy’S Lab Inc Dr Use of storage stable viscous phospholipid depot to treat wounds
WO2012135856A2 (fr) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Vinorelbine à très faible dose pour le traitement du cancer
CN102743337B (zh) * 2011-04-20 2014-04-16 国家纳米科学中心 一种纳米粒子药物组合物及其制备方法
WO2012170796A1 (fr) * 2011-06-09 2012-12-13 Amylin Pharmaceuticals, Inc. Compositions de gels
WO2013059922A1 (fr) 2011-10-25 2013-05-02 The University Of British Columbia Nanoparticules lipides de taille limite, et procédés correspondants
EP2846773A4 (fr) 2012-05-10 2015-12-30 Painreform Ltd Préparations de dépôt d'un anesthésiant local et procédés de préparation associés
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US20160290093A1 (en) * 2015-04-02 2016-10-06 Baker Hughes Incorporated Disintegrating Compression Set Plug with Short Mandrel
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
US20240024339A1 (en) * 2020-11-19 2024-01-25 Nippon Kayaku Kabushiki Kaisha Composition containing water-soluble drug causing vascular disorder, solution for use in preparation of administration solution containing water-soluble drug causing vascular disorder, kit, agent for suppressing vascular disorder, and solution containing nonionic surfactant
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224042A (en) * 1880-02-03 Music-rest for piano-fortes
US670001A (en) * 1900-02-15 1901-03-19 Stephen B Morss Combined curb and gutter.
US4816247A (en) 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
AU630469B2 (en) 1989-05-26 1992-10-29 Abbott Laboratories Injectable clarithromycin composition
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
CA2231682A1 (fr) 1995-09-13 1997-03-20 Junzo Seki Preparation lyophilisee contenant de la pge1 et son procede de production
CA2259179C (fr) * 1996-07-03 2008-09-23 University Of Pittsburgh Formulations d'emulsions pour des agents actifs hydrophiles
JP3455233B2 (ja) * 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP2003277281A (ja) * 2002-03-20 2003-10-02 Kumamoto Technology & Industry Foundation 静脈炎の予防及び治療のための医薬
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
JP4426749B2 (ja) * 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
CN1925853B (zh) * 2004-07-28 2011-01-26 陈献 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物
CN1634058A (zh) * 2004-10-20 2005-07-06 李晓祥 长春瑞滨乳剂及其制备方法

Also Published As

Publication number Publication date
JP4643641B2 (ja) 2011-03-02
RS20070029A (sr) 2008-11-28
EA200700312A1 (ru) 2007-08-31
WO2006017246A3 (fr) 2006-03-30
US20110082168A1 (en) 2011-04-07
EA012522B1 (ru) 2009-10-30
CA2578574C (fr) 2013-09-10
HK1100062A1 (en) 2007-09-07
MX2007000416A (es) 2007-03-28
US8026250B2 (en) 2011-09-27
TW200607525A (en) 2006-03-01
US20130029918A1 (en) 2013-01-31
CA2578574A1 (fr) 2006-02-16
AU2005271873A1 (en) 2006-02-16
US20060008480A1 (en) 2006-01-12
US8222268B2 (en) 2012-07-17
ZA200701167B (en) 2010-08-25
WO2006017246A2 (fr) 2006-02-16
EP1773294A2 (fr) 2007-04-18
NO20070785L (no) 2007-04-02
EP1773294A4 (fr) 2012-11-21
JP2008505972A (ja) 2008-02-28
IL180350A0 (en) 2007-06-03
ECSP077238A (es) 2007-04-26
US20120046310A1 (en) 2012-02-23
BRPI0513178A (pt) 2008-04-29
CN1859898B (zh) 2011-06-08
US7871632B2 (en) 2011-01-18
KR20070032816A (ko) 2007-03-22
CN1859898A (zh) 2006-11-08

Similar Documents

Publication Publication Date Title
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2007149406A3 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
EP1858926A4 (fr) Glycosaminoglycanases solubles et procédés de préparation et d'utilisation de glycosaminoglycanases solubles
WO2006060547A3 (fr) Systemes et methodes d'administration intra-orale de medicaments
IS6994A (is) Arípíprazóllausn til gjafar um munn
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
FR2851470B1 (fr) Composition pharmaceutique pour administration transdermique ou transmuqueuse
WO2005115398A3 (fr) Inhibiteurs d'integrase de vih
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
WO2007025005A3 (fr) Formulations de nalbuphine a liberation prolongee
TW200626132A (en) Topical nepafenac formulations
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
EP2164518A4 (fr) Formulations pour l'administration par voie orale d'agents thérapeutiques, et procédés associés
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
WO2003041656A3 (fr) Systeme de liberation prolongee de medicaments solubles
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
NO20064783L (no) Opplosningstabeletter med licarbazepin
WO2006064228A3 (fr) Composes